Radiation therapy in prostate cancer: A risk-adapted strategy

Current Oncology

Volumn 17, Issue SUPPL. 2, 2010, Pages

  Hayden, A J ^a   Catton, C ^b   Pickles, Tom ^c  

^a Cancer Agency   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Adjuvant androgen deprivation therapy; Brachytherapy; Nomogram; Prostatic neoplasms; Radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADVERSE OUTCOME; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROL STRATEGY; CYTOREDUCTIVE SURGERY; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HIGH RISK POPULATION; HUMAN; IATROGENIC DISEASE; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SELECTION; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PROGNOSIS; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; RADIATION HAZARD; RADICAL RETROPUBIC PROSTATECTOMY; RECURRENCE RISK; RISK ASSESSMENT; RISK FACTOR; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 78149443617     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v17i0.704     Document Type: Article

References (60)

1. National Comprehensive Cancer Network (nccn). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer V.2.2010. Fort Washington, PA: nccn; 2010. [Available online at: www.nccn.org/professionals/physician_gls/PDF/prostate. pdf (free registration required); cited June 16, 2010]
2. Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007;69:1095-101.
3. Schroeck FR, Kattan MW, Moul JW, et al. Re-calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy. BJU Int 2009;105:1654-9.
4. Giberti C, Chiono L, Gallo F, Schenone M, Gastaldi E. Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study. World J Urol 2009;27:607-12.
5. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy < 72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/ external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:25-33.
6. Ash D, Flynn A, Battermann J, de Reijke T, Lavagnini P, Blank L. estro/eau/eortc recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000;57:315-21.
7. Taira AV, Merrick GS, Galbreath RW, Wallner KE, Butler WM. Natural history of clinically staged low-and intermediaterisk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2010;76:349-54.
8. Morris W, Keyes M, Palma D, et al. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low-and intermediate-risk prostate cancer. Urology 2009;73:860-5.
9. Potters L, Morgenstern C, Calugaru E, et al. 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005;173:1562-6.
10. Sylvester JE, Grimm PD, Eulau SM, Takamiya RK, Naidoo D. Permanent prostate brachytherapy preplanned technique: the modern Seattle method step-by-step and dosimetric outcomes. Brachytherapy 2009;8:197-206.
11. Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007;67:327-33.
12. Sylvester JE, Grimm PD, Blasko JC, et al. 15-Year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys 2007;67:57-64.
13. Galalae RM, Martinez A, Mate T, et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (hdr-bt) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:1048-55.
14. Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999;353:267-72.
15. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 2010;28:1106-11.
16. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the MD Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67-74.
17. Al-Mamgani A, Van Putten WLJ, Heemsbergen WD, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;72:980-8.
18. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the mrc RT01 randomised controlled trial. Lancet Oncol 2007;8:475-87.
19. Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a metaanalysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009;74:1405-18.
20. Huang EH, Pollack A, Levy L, et al. Late rectal toxicity: dose- volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2002;54:1314-21.
21. Peeters STH, Heemsbergen WD, van Putten WLJ, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 2005;61:1019-34.
22. Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:1124-9.
23. Jarad M, Andrew B, Robert B, et al. Image guided dose escalated prostate radiotherapy: still room to improve. Radiat Oncol 2009;4:50. [Erratum in: Radiat Oncol 2009;4:65]
24. Miles EF, Lee R. Hypofractionation for prostate cancer: a critical review. Semin Radiat Oncol 2008;18:41-7.
25. Wilt TJ, Shamliyan TA, Taylor BC, MacDonald R, Kane RL. Association between hospital and surgeon radical prostatectomy volume and patient outcomes: a systematic review. J Urol 2008;180:820-9.
26. Suekane S, Noguchi M, Nakashima O, Yamada S, Kojiro M, Matsuoka K. Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy. Int J Urol 2007;14:713-18.
27. Eisenberg ML, Cowan JE, Davies BJ, Carroll PR, Shinohara K. The importance of tumor palpability and transrectal ultrasonographic appearance in the contemporary clinical staging of prostate cancer. Urol Oncol 2009;:. [Epub ahead of print]
28. Potdevin L, Ercolani M, Jeong J, Kim IY. Functional and oncologic outcomes comparing interfascial and intrafascial nerve sparing in robot-assisted laparoscopic radical prostatectomies. J Endourol 2009;23:1479-84.
29. Zorn KC, Wille MA, Thong AE, et al. Continued improvement of perioperative, pathological and continence outcomes during 700 robot-assisted radical prostatectomies. Can J Urol 2009;16:4742-9.
30. Choo R, Hruby G, Hong J, et al. (In)-efficacy of salvage radiotherapy for rising psa or clinically isolated local recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys 2002;53:269-76.
31. Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009;27:4300-5.
32. Audenet F, Comperat E, Seringe E, et al. Oncologic control obtained after radical prostatectomy in men with a pathological Gleason score ≥8: a single-center experience. Urol Oncol 2009;:. [Epub ahead of print]
33. Boorjian SA, Blute ML. Surgical management of high risk prostate cancer: the Mayo Clinic experience. Urol Oncol 2008;26:530-2.
34. Kawamorita N, Saito S, Ishidoya S, et al. Radical prostatectomy for high-risk prostate cancer: biochemical outcome. Int J Urol 2009;16:733-8.
35. Swindle P, Eastham JA, Ohori M, et al. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 2005;174:903-7.
36. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy: patterns of recurrence and cancer control. Urol Clin North Am 1997;24:395-406.
37. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (eortc trial 22911). Lancet 2005;366:572-8.
38. Wiegel T, Bottke D, Steiner U, et al. Phase iii postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: aro 96-02/ auo ap 09/95. J Clin Oncol 2009;27:2924-30.
39. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009;181:956-62.
40. Stephenson AJ, Eastham JA. Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol 2005;23:8198-203.
41. Sia M, Pickles T, Morton G, Souhami L, Lukka H, Warde P. Salvage radiotherapy following biochemical relapse after radical prostatectomy: proceedings of the Genito-Urinary Radiation Oncologists of Canada consensus meeting. Can Urol Assoc J 2008;2:500-7.
42. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an eortc study): a phase iii randomised trial. Lancet 2002;360:103-8.
43. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516-27.
44. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma- long-term results of phase iii rtog 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285-90.
45. Pilepich MV, Winter K, John MJ, et al. Phase iii radiation therapy oncology group (rtog) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-52.
46. Lawton CA, Winter K, Grignon D, Pilepich MV. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol 2005;23:800-7.
47. Williams SG, Pickles T, Buyyounouski MK, Kestin LL, Duchesne GM. The optimum duration of combination androgen deprivation therapy (adt) with prostate cancer radiotherapy: determining the duration-benefit relationship from multiinstitutional analysis. Int J Radiat Oncol Biol Phys 2010;:. [In press]
48. Zietman AL, Prince EA, Nakfoor BM, Park JJ. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys 1997;38:1067-70.
49. Pickles T, for the Prostate Cohort Outcomes Initiative. Duration, not timing is important when androgen ablation is combined with external beam rt [abstract]. Can J Urol 2004;11:2232.
50. McGowan D, Hunt D, Jones CU, et al. Short-term endocrine therapy prior to and during radiation therapy improves overall survival in patients with T1b-T2b adenocarcinoma of the prostate and psa ≤20: initial results of rtog 94-08 [abstract]. Int J Radiat Oncol Biol Phys 2010;77:1.
51. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004;292:821-7.
52. Klotz L, Gleave M, Goldenberg S. Neoadjuvant hormone therapy: the Canadian trials. Mol Urol 2000;4:233-7.
53. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (spcg-7/sfuo-3): an open randomised phase iii trial. Lancet 2009;373:301-8.
54. Pollack A, Salem N, Ashoori F, et al. Lack of prostate cancer radiosensitization by androgen deprivation. Int J Radiat Oncol Biol Phys 2001;51:1002-7.
55. Vergis R, Corbishley CM, Norman AR, et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 2008;9:342-51.
56. Nesslinger NJ, Sahota RA, Stone B, et al. Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res 2007;13:1493-502.
57. Segal RJ, Reid RD, Courneya KS, et al. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 2009;27:344-51.
58. Duncan GG, Corbett T, Lukka H, Warde P, Pickles T. gu radiation oncologists consensus on bone loss from androgen deprivation. Can J Urol 2006;13:2962-6.
59. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-56.
60. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of rtog 92-02. Eur Urol 2008;54:816-24.